



February 4, 2019

Company name: SanBio Co., Ltd.  
Representative: Keita Mori, Representative Director  
and President  
(TSE Mothers Code: 4592)  
Contact: Yoshihiro Kakutani, Corporate Officer  
of Management Administration  
(TEL: +81-3-6264-3481)

### **Notice Concerning the Appointment of a New Corporate Officer**

SanBio Co., Ltd. hereby announces that the following new corporate officer has assumed his office as of February 1, 2019:

1. New corporate officer (as of February 1, 2019)

Name	Title and responsibilities
Hiroshi Yamamoto	Corporate Officer Head, Commercial (Japan/Asia)

2. Career summary of Corporate Officer and Head, Commercial (Japan/Asia) Hiroshi Yamamoto

Name	Career summary
Hiroshi Yamamoto (born April 18, 1981)	April 2004 Joined Eisai Co., Ltd.
	October 2013 Joined AbbVie Inc.
	May 2014 Joined Santen Pharmaceutical Co., Ltd.
	April 2016 President, Santen Pharmaceutical Asia Pte. Ltd.
	July 2018 Vice president, Santen Pharmaceutical (China) Co., Ltd.
	February 2019 Joined SanBio Co., Ltd.

3. Mr. Hiroshi Yamamoto's involvement with the SanBio Group

Mr. Yamamoto started his career as a domestic sales representative for Japanese market at Eisai Co., Ltd. and later was in charge of marketing and business strategies throughout Asia, including organizational restructuring and corporate planning and management. Next at AbbVie Inc., Mr. Yamamoto worked as the head of product launch strategies for new medicines designed to treat Parkinson's disease and other diseases affecting cerebral nerves, from their planning stages to their execution. Then, as a member of Santen Pharmaceutical Co., Ltd., he served as president of Santen Pharmaceutical Asia Pte. Ltd., establishing local subsidiaries and overseeing company operations in the ASEAN region. He later served as vice president of Santen Pharmaceutical (China) Co., Ltd., where he formulated, executed, and managed long-term strategies related to the China business. Mr. Yamamoto has abundant experience conducting business development and management for major pharmaceutical companies in Japan and Asia. SanBio is prioritizing the prompt establishment of a post-launch framework for its SB623 regenerative cell medicine program for the treatment of chronic motor deficit from traumatic brain injury (TBI) in Japan and will fully utilize Mr. Yamamoto's experience when conducting domestic post-launch expansion. However, the scope of this personnel change is not limited to Japan, as SanBio believes that Mr. Yamamoto's experience will be of assistance to future expansion throughout Asia.